| Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS) K Anand, J Ensor, B Trachtenberg, EH Bernicker Cardio Oncology 1 (2), 172-178, 2019 | 105 | 2019 |
| A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer AW Chung, K Anand, AC Anselme, AA Chan, N Gupta, LA Venta, ... Science Translational Medicine 13 (624), eabj5070, 2021 | 59 | 2021 |
| Clinical utility of reflex ordered testing for molecular biomarkers in lung adenocarcinoma K Anand, TL Phung, EH Bernicker, PT Cagle, RJ Olsen, JS Thomas Clinical Lung Cancer 21 (5), 437-442, 2020 | 38 | 2020 |
| Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors K Anand, G Sahu, E Burns, A Ensor, J Ensor, SR Pingali, V Subbiah, ... ESMO Open 5 (4), e000866, 2020 | 38 | 2020 |
| Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma K Anand, J Roszik, D Gombos, J Upshaw, V Sarli, S Meas, A Lucci, C Hall, ... Cancers 11 (6), 856, 2019 | 35 | 2019 |
| T-cell lymphoma secondary to checkpoint inhibitor therapy K Anand, J Ensor, SR Pingali, P Hwu, M Duvic, S Chiang, R Miranda, ... Journal for immunotherapy of cancer 8 (1), 2020 | 33 | 2020 |
| A Phase II study of the efficacy and safety of Chloroquine in combination with Taxanes in the treatment of patients with advanced or metastatic anthracycline-refractory breast … K Anand, P Niravath, T Patel, J Ensor, A Rodriguez, T Boone, ST Wong, ... Clinical breast cancer 21 (3), 199-204, 2021 | 27 | 2021 |
| Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-cell (CAR-T) Therapy: Recognition, Risk Factors, and Management EA Burns, C Gentille, B Trachtenberg, SR Pingali, K Anand Diseases 9 (1), 20, 2021 | 26 | 2021 |
| Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors EA Burns, IN Muhsen, K Anand, J Xu, G Umoru, AN Arain, M Abdelrahim Journal of Immunotherapy (Hagerstown, Md.: 1997) 44 (3), 132, 2021 | 25 | 2021 |
| Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review K Anand, EA Burns, J Ensor, L Rice, SR Pingali Clinical Lymphoma Myeloma and Leukemia 20 (1), 18-23, 2020 | 25 | 2020 |
| Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy K Anand, T Patel, P Niravath, A Rodriguez, J Darcourt, A Belcheva, ... Scientific reports 11 (1), 1-8, 2021 | 22 | 2021 |
| Global ophthalmology practice patterns during COVID-19 pandemic and lockdown S Sanjay, SW Leo, KG Au Eong, GA Adriono, KCS Fong, K Anand, ... Ophthalmic Epidemiology, 1-12, 2021 | 14 | 2021 |
| Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. K Anand, E Burns, D Sano, SR Pingali, J Westin, LJ Nastoupil, HJ Lee, ... Journal of Clinical Oncology 37 (15_suppl), 2540-2540, 2019 | 11 | 2019 |
| Comparative review of 30 day non-relapse mortality (NRM) in B-cell lymphomas associated with anti-CD19 chimeric antigen receptor T-cells (CAR-T) from FDA database, clinical … E Burns, K Anand, JR Westin, SRK Pingali, J Ensor, D Sano, LJ Nastoupil, ... Blood 134, 1931, 2019 | 9 | 2019 |
| Acupuncture and vitamin D for the management of aromatase inhibitor-induced arthralgia K Anand, P Niravath Current oncology reports 21 (6), 1-8, 2019 | 9 | 2019 |
| Primary diffuse large B-cell lymphoma of the uterus: A SEER database analysis AM Ensor, CG Sanchez, JE Ensor, K Anand Medicine 100 (40), 2021 | 8 | 2021 |
| Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy KR Chitturi, EA Burns, IN Muhsen, K Anand, BH Trachtenberg Current Oncology Reports, 1-17, 2022 | 7 | 2022 |
| Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM) EA Burns, JE Ensor, K Anand, C Gentille, C Guerrero, RB Kieser, ... Blood 138, 4740, 2021 | 7 | 2021 |
| Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes. SP Iyer, J Ensor, K Anand, P Hwu, V Subbiah, C Flowers, ... medRxiv, 2020 | 7 | 2020 |
| Complete response to R-EPOCH in primary cardiac lymphoma K Anand, SR Pingali, B Trachtenberg, SP Iyer Case Reports in Hematology 2019, 2019 | 7 | 2019 |
Joe EnsorResearch Scientist在 houstonmethodist.org 的电子邮件经过验证
